191 related articles for article (PubMed ID: 34890875)
1. Improving antibody drug development using bionanotechnology.
Makowski EK; Schardt JS; Tessier PM
Curr Opin Biotechnol; 2022 Apr; 74():137-145. PubMed ID: 34890875
[TBL] [Abstract][Full Text] [Related]
2. Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods.
Makowski EK; Wu L; Gupta P; Tessier PM
MAbs; 2021; 13(1):1895540. PubMed ID: 34313532
[TBL] [Abstract][Full Text] [Related]
3. Biophysical and Sequence-Based Methods for Identifying Monovalent and Bivalent Antibodies with High Colloidal Stability.
Alam ME; Geng SB; Bender C; Ludwig SD; Linden L; Hoet R; Tessier PM
Mol Pharm; 2018 Jan; 15(1):150-163. PubMed ID: 29154550
[TBL] [Abstract][Full Text] [Related]
4. Improving monoclonal antibody selection and engineering using measurements of colloidal protein interactions.
Geng SB; Cheung JK; Narasimhan C; Shameem M; Tessier PM
J Pharm Sci; 2014 Nov; 103(11):3356-3363. PubMed ID: 25209466
[TBL] [Abstract][Full Text] [Related]
5. Measurements of Monoclonal Antibody Self-Association Are Correlated with Complex Biophysical Properties.
Geng SB; Wittekind M; Vigil A; Tessier PM
Mol Pharm; 2016 May; 13(5):1636-45. PubMed ID: 27045771
[TBL] [Abstract][Full Text] [Related]
6. Physicochemical Rules for Identifying Monoclonal Antibodies with Drug-like Specificity.
Zhang Y; Wu L; Gupta P; Desai AA; Smith MD; Rabia LA; Ludwig SD; Tessier PM
Mol Pharm; 2020 Jul; 17(7):2555-2569. PubMed ID: 32453957
[TBL] [Abstract][Full Text] [Related]
7. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
[TBL] [Abstract][Full Text] [Related]
8. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
[TBL] [Abstract][Full Text] [Related]
9. Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties.
Svilenov HL; Arosio P; Menzen T; Tessier P; Sormanni P
MAbs; 2023; 15(1):2164459. PubMed ID: 36629855
[TBL] [Abstract][Full Text] [Related]
10. Discovery of highly soluble antibodies prior to purification using affinity-capture self-interaction nanoparticle spectroscopy.
Wu J; Schultz JS; Weldon CL; Sule SV; Chai Q; Geng SB; Dickinson CD; Tessier PM
Protein Eng Des Sel; 2015 Oct; 28(10):403-14. PubMed ID: 26363633
[TBL] [Abstract][Full Text] [Related]
11. An alternative assay to hydrophobic interaction chromatography for high-throughput characterization of monoclonal antibodies.
Estep P; Caffry I; Yu Y; Sun T; Cao Y; Lynaugh H; Jain T; Vásquez M; Tessier PM; Xu Y
MAbs; 2015; 7(3):553-61. PubMed ID: 25790175
[TBL] [Abstract][Full Text] [Related]
12. Ultradilute Measurements of Self-Association for the Identification of Antibodies with Favorable High-Concentration Solution Properties.
Starr CG; Makowski EK; Wu L; Berg B; Kingsbury JS; Gokarn YR; Tessier PM
Mol Pharm; 2021 Jul; 18(7):2744-2753. PubMed ID: 34105965
[TBL] [Abstract][Full Text] [Related]
13. Rapid analysis of antibody self-association in complex mixtures using immunogold conjugates.
Sule SV; Dickinson CD; Lu J; Chow CK; Tessier PM
Mol Pharm; 2013 Apr; 10(4):1322-31. PubMed ID: 23383873
[TBL] [Abstract][Full Text] [Related]
14. Selecting and engineering monoclonal antibodies with drug-like specificity.
Starr CG; Tessier PM
Curr Opin Biotechnol; 2019 Dec; 60():119-127. PubMed ID: 30822699
[TBL] [Abstract][Full Text] [Related]
15. Facile Preparation of Stable Antibody-Gold Conjugates and Application to Affinity-Capture Self-Interaction Nanoparticle Spectroscopy.
Geng SB; Wu J; Alam ME; Schultz JS; Dickinson CD; Seminer CR; Tessier PM
Bioconjug Chem; 2016 Oct; 27(10):2287-2300. PubMed ID: 27494306
[TBL] [Abstract][Full Text] [Related]
16. Cross-interaction chromatography: a rapid method to identify highly soluble monoclonal antibody candidates.
Jacobs SA; Wu SJ; Feng Y; Bethea D; O'Neil KT
Pharm Res; 2010 Jan; 27(1):65-71. PubMed ID: 19911257
[TBL] [Abstract][Full Text] [Related]
17. Emerging methods for identifying monoclonal antibodies with low propensity to self-associate during the early discovery process.
Tessier PM; Wu J; Dickinson CD
Expert Opin Drug Deliv; 2014 Apr; 11(4):461-5. PubMed ID: 24444112
[TBL] [Abstract][Full Text] [Related]
18. Product-Specific Impact of Viscosity Modulating Formulation Excipients During Ultra-High Concentration Biotherapeutics Drug Product Development.
Rodrigues D; Tanenbaum LM; Thirumangalathu R; Somani S; Zhang K; Kumar V; Amin K; Thakkar SV
J Pharm Sci; 2021 Mar; 110(3):1077-1082. PubMed ID: 33340533
[TBL] [Abstract][Full Text] [Related]
19. Antibodies with Weakly Basic Isoelectric Points Minimize Trade-offs between Formulation and Physiological Colloidal Properties.
Gupta P; Makowski EK; Kumar S; Zhang Y; Scheer JM; Tessier PM
Mol Pharm; 2022 Mar; 19(3):775-787. PubMed ID: 35108018
[TBL] [Abstract][Full Text] [Related]
20. High-throughput screening for developability during early-stage antibody discovery using self-interaction nanoparticle spectroscopy.
Liu Y; Caffry I; Wu J; Geng SB; Jain T; Sun T; Reid F; Cao Y; Estep P; Yu Y; Vásquez M; Tessier PM; Xu Y
MAbs; 2014; 6(2):483-92. PubMed ID: 24492294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
